Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Adamas Pharmaceuticals Inc (ADMS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2020 Financial Results"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2019 Financial Results"
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Adamas Reports First Quarter 2019 Financial Results - First quarter net product sales of $11.7 million - GOCOVRI ® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., -- Adamas Pharmaceuticals, Inc. , a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2019, as well as recent corporate developments. “We remain focused on driving the growth of GOCOVRI for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, and completing our Phase 3 study of ADS-5102 for walking impair..."
11/01/2018 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2018 Financial Results - GOCOVRI™ extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions - EMERYVILLE, Calif., – Adamas Pharmaceuticals, Inc. , a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today reported financial results and pipeline updates for the third quarter ended September 30, 2018. “We have established a strong foundation and remain focused on increasing the utilization of GOCOVRI in Parkinson’s disease patients with dyskinesia and OFF,” stated Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “In addition, we’re pleased with the robust enrollment of the Phase 3 study of AD..."
05/03/2018 8-K Quarterly results
Docs: "Adamas Reports First Quarter 2018 Financial Results GOCOVRI™ extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S. Food and Drug Administration on the clinical development program for ADS-4101 in patients with epilepsy"
11/02/2017 8-K Quarterly results
Docs: "Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results"
08/08/2017 8-K Quarterly results
Docs: "Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results"
05/09/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
05/10/2016 8-K Quarterly results
Docs: "Adamas Reports First Quarter 2016 Financial Results"
02/23/2016 8-K Quarterly results
Docs: "Adamas Reports Fourth Quarter and Full Year 2015 Financial Results Emeryville, Calif., — Adamas Pharmaceuticals, Inc. today announced financial results for the fourth quarter"
11/12/2015 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2015 Financial Results Emeryville, Calif., November 12, 2015"
08/11/2015 8-K Quarterly results
Docs: "ADAMAS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS"
05/13/2015 8-K Quarterly results
Docs: "ADAMAS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
03/03/2015 8-K Quarterly results
Docs: "ADAMAS REPORTS FISCAL 2014 FINANCIAL RESULTS"
11/04/2014 8-K Quarterly results
Docs: "ADAMAS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
08/07/2014 8-K Quarterly results
Docs: "ADAMAS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
05/13/2014 8-K Quarterly results
Docs: "ADAMAS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy